New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
08:03 EDTNKTRNektar appoints Ivan Gergel Chief Medical Officer effective today
Gergel most recently served as Executive Vice President, Research & Development of Endo Pharmaceuticals (ENDP) and Chief Scientific Officer.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
10:14 EDTNKTRFDA grants QIDP designation to Bayer's Amikacin Inhale, Ciprofloxacin DPI
Subscribe for More Information
November 20, 2014
09:05 EDTNKTRNektar presents preclinical study findings for etirinotecan pegol combination
Nektar Therapeutics announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. The preclinical study results demonstrated that all dose combinations of NKTR-102 and rucaparib were well-tolerated, synergistic, and led to 100% prolonged survival in this tumor model. These data were presented during the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. NKTR-102 and rucaparib in combination exhibited marked synergy, demonstrated by durable complete responses, even at the lowest doses of both agents dosed in combination. The combination of NKTR-102 and rucaparib was tolerated at all dose levels. Doses used in this study provide exposures of NKTR-102 and rucaparib that are achievable clinically, underscoring the translational relevance of these results. Combination studies of NKTR-102 and rucaparib are ongoing in patient-derived xenograft models in collaboration with Professor Paul Haluska at Mayo Clinic and Clovis Oncology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use